ABSTRACT
About ENT Disorder Treatment
ENT also known as otolaryngology, is an area of medicine that deals with disorders of ear, nose, and throat. Dysfunction of these body parts can affect quality of life and in certain cases may even lead to medical emergency. The market encompasses drugs that are used for the treatment of the ENT disorder. It mainly considers the various drug class used for the treatment of numerous symptoms of the disease. The major ENT disorders included in the report are rhinitis, sinusitis, otitis media, and tonsillitis.
Technavio’s analysts forecast the global ENT disorder treatment market to grow at a CAGR of 2.17% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global ENT disorder treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales from both branded and generic drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global ENT Disorder Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• ALK
• GSK
• Novartis
• Sanofi
Other prominent vendors
• Allergan
• AstraZeneca
• Dr. Reddy's Laboratories
• Lupin
• Merck
• Mylan
• Otonomy
• Pfizer
• Sun Pharma
• Teva Pharmaceuticals
Market driver
• Deteriorating environmental conditions.
• For a full, detailed list, view our report
Market challenge
• Growing cases of anti-bacterial resistance.
• For a full, detailed list, view our report
Market trend
• Growing consolidation in industry particularly for rhinitis.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by disease
• Global rhinitis treatment market
• Global sinusitis treatment market
• Global otitis media treatment market
• Global tonsillitis treatment market
PART 09: Geographical segmentation
• ENT disorder treatment market in Americas
• ENT disorder treatment market in EMEA
• ENT disorder treatment market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments
PART 12: Market trends
• Growing consolidation in industry particularly for rhinitis
• Increase in research on allergic disorders
• Awareness about controlled usage of antibiotics
PART 13: Vendor landscape
• Competitive landscape
PART 14: Key vendor analysis
• ALK
• GSK
• Novartis
• Sanofi
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits?
Exhibit 01: Some major treatments associated with sinusitis
Exhibit 02: Snapshot: Global ENT disorder treatment market
Exhibit 03: Global ENT disorder treatment market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis: Global ENT disorder treatment market
Exhibit 05: Five forces analysis
Exhibit 06: Key pipeline by vendors
Exhibit 07: Pipeline landscape
Exhibit 08: Global ENT disorder treatment market segmentation by disease type
Exhibit 09: Market snapshot: Global ENT disorder market by disease type 2016-2021
Exhibit 10: Types of rhinitis
Exhibit 11: Major types of allergic rhinitis
Exhibit 12: Global rhinitis treatment market 2016-2021 ($ millions)
Exhibit 13: Types of sinusitis
Exhibit 14: Some drugs approved for sinusitis
Exhibit 15: Global sinusitis treatment market 2016-2021 ($ millions)
Exhibit 16: Otitis media therapy in pipeline
Exhibit 17: Global otitis media treatment market 2016-2021 ($ millions)
Exhibit 18: Global tonsillitis treatment market 2016-2021 ($ millions)
Exhibit 19: ENT disorder treatment market by geography 2016 and 2021
Exhibit 20: ENT disorder treatment market by geography 2016-2021 ($ millions)
Exhibit 21: Market scenario in Americas
Exhibit 22: ENT disorder treatment market in Americas 2016-2021 ($ millions)
Exhibit 23: Market scenario in EMEA
Exhibit 24: ENT disorder treatment market in EMEA 2016-2021 ($ millions)
Exhibit 25: Market scenario in APAC
Exhibit 26: ENT disorder treatment market in APAC 2016-2021 ($ millions)
Exhibit 27: ENT disorders triggered by various pollutants
Exhibit 28: Adult population with sinusitis and chronic rhinitis in US 2014 (million)
Exhibit 29: Impact of drivers
Exhibit 30: Antibiotic resistance development steps
Exhibit 31: Few landmark generic version of branded drugs
Exhibit 32: Impact of challenges
Exhibit 33: Major causes of antibiotic resistance
Exhibit 34: Competitive structure analysis of global ENT disorder treatment market 2016
Exhibit 35: Competitive analysis of global ENT disorder treatment market
Exhibit 36: ALK: Key highlights
Exhibit 37: ALK: Strength assessment
Exhibit 38: ALK: Strategy assessment
Exhibit 39: ALK: Opportunity assessment
Exhibit 40: GSK: Key highlights
Exhibit 41: GSK: Strength assessment
Exhibit 42: GSK: Strategy assessment
Exhibit 43: GSK: Opportunity assessment
Exhibit 44: GSK: YoY growth rate of Avamys/Veramyst 2014 and 2015 ($ millions)
Exhibit 45: Novartis: Key highlights
Exhibit 46: Novartis: Strength assessment
Exhibit 47: Novartis: Strategy assessment
Exhibit 48: Novartis: Opportunity assessment
Exhibit 49: Sanofi: Key highlights
Exhibit 50: Sanofi: Strength assessment
Exhibit 51: Sanofi: Strategy assessment
Exhibit 52: Sanofi: Opportunity assessment
Exhibit 53: Sanofi: YoY growth rate of Allegra 2014 and 2015 ($ millions)
